NeuroSense Therapeutics Ltd. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| CLEAR STREET LLC | 02/14/2025 | 65,659 | $29,000 | -0.15% | 0.36% |
| CITADEL ADVISORS LLC | 02/14/2025 | 22,711 | $7,040 | -10.14% | 0.13% |
| WARBERG ASSET MANAGEMENT LLC | 02/13/2025 | 17,936 | $7,892 | -11.21% | 0.10% |
| UBS GROUP AG | 02/14/2025 | 94 | $41 | -53.00% | 0.00% |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
NeuroSense Therapeutics Ltd. institutional Ownership - FAQ's
During the previous two years, 5 institutional investors and hedge funds held shares of NeuroSense Therapeutics Ltd.. The most heavily invested institutionals were:
CLEAR STREET LLC: 65,659
CITADEL ADVISORS LLC: 22,711
Warberg Asset Management LLC: 17,936
UBS Group AG: 94
Empery Asset Management, LP: 160,000
0.59% of NeuroSense Therapeutics Ltd. stock is owned by institutional investors.
Institutional investors have bought a total of 266,400 shares in the last 24 months. This purchase volume represents approximately $53,280 in transactions.